For Healthcare Professionals

Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

clipboard-pencil

About the study

The purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against acetylcholine receptor (AChR).
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

  1. Diagnosis of MG with generalized muscle weakness meeting the clinical criteria defined by Myasthenia Gravis Foundation of America (MGFA) Class II, III or IV
  2. Positive serological test for autoantibodies against AChR

EXCLUSION CRITERIA

Exclusion Criteria:

  1. History of thymectomy, or any other thymic surgery within 12 months prior to Screening
  2. Untreated thymic malignancy, carcinoma, or thymoma
  3. History of Neisseria meningitidis infection
  4. Pregnancy, breastfeeding, or intention to conceive during the course of the study
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.

Study’s details


Contition

Generalized Myasthenia Gravis

Age (in years)

18+

Phase

Phase 3

Participants needed

254

Est. Completion Date

Jul 7, 2027

Treatment type

Interventional


Sponsor

Alexion Pharmaceuticals, Inc.

ClinicalTrials.gov identifier

NCT05556096

Study number

ALXN1720-MG-301

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.